文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌与上尿路尿路上皮癌的遗传差异及其治疗意义

Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.
PubMed 文献 · Eur Urol Oncol · 2020-12-30

本综述系统检索截至2020年2月的文献,总结膀胱尿路上皮癌(BUC)与上尿路尿路上皮癌(UTUC)的遗传差异。两者共享FGFR3、TP53、HRAS及表观遗传基因突变但频率不同,UTUC更常为管腔型且T细胞耗竭更明显,克隆研究提示异时性复发倾向相应亚型,提示应作为相关但不同的实体治疗。

要点

  • UTUC与BUC共享FGFR3、TP53、HRAS及KDM6A、KMT2A-C等基因突变,但频率不同。
  • UTUC更常为管腔型且T细胞耗竭更明显,BUC后发生的UTUC常为基底型。
  • 两者及其异时性复发应视为相关但不同的实体,指导部位特异性治疗。

核心结论

  • UTUC与BUC共享许多基因组改变但频率不同,这些差异可能影响肿瘤行为,两者及异时性复发应作为相关但不同的实体治疗。

研究设计与样本

  • 本综述系统检索PubMed、Cochrane和Web of Science数据库至2020年2月,关键词包括urothelial carcinomas、upper urinary tract、renal pelvis、ureter、bladder cancer和genetics。

主要发现

  • UTUC与BUC在FGFR3、TP53、HRAS及表观遗传基因KDM6A和KMT2A-C等共享突变,但频率不同。
  • UTUC与BUC的亚型分析显示相似表达亚型,但UTUC更常为管腔型且T细胞耗竭更明显。
  • 克隆研究表明BUC后发生的UTUC常为基底型,而UTUC后发生的BUC可能为管腔型。

临床怎么用

  • 应认识到UTUC与BUC的遗传差异,针对不同部位肿瘤制定个体化治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Bladder urothelial carcinoma (BUC) and upper tract urothelial carcinoma (UTUC) have genetic differences, which may influence therapy. OBJECTIVE: The aim of the current review was to summarize the current genetic understanding of upper tract and BUC. EVIDENCE ACQUISITION: PubMed, Cochrane, and Web of Science online databases were searched systematically up to February 2020, using the following keywords: urothelial carcinomas, upper urinary tract, renal pelvis, ureter, bladder cancer, and genetics. EVIDENCE SYNTHESIS: UTUC and BUC share mutations in similar genes, such as FGFR3, TP53, and HRAS, and epigenetic genes, such as KDM6A and KMT2A-C, but at varying frequencies. Furthermore, subtyping of UTUC and BUC has identified similar expression subtypes, but UTUC is more often luminal with more T-cell depletion. Clonal studies indicate that BUC after UTUC is also likely luminal, while UTUC after BUC is often basal. CONCLUSIONS: UTUC and BUC share many genomic alterations, but at different frequencies, which recapitulate with their metachronous recurrences. These differences likely contribute to the behavior of these two cancers and imply that they and their metachronous recurrences should be treated as two related yet distinct entities. PATIENT SUMMARY: Urothelial carcinoma of the bladder has distinct genomic features, which are different from distinct genomic features of urothelial carcinoma of the renal pelvis and/or ureter. These features can be used for tailored treatment options specific to tumors of different locations.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sfakianos JP, Gul Z, Shariat SF, et al. Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. Eur Urol Oncol. 2020. PMID: 33386276. doi:10.1016/j.euo.2020.12.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。